



Published in final edited form as:

*Clin J Sport Med.* 2011 September ; 21(5): 447–453. doi:10.1097/JSM.0b013e318221299c.

## Efficacy of Treatment of Trochanteric Bursitis: A Systematic Review

David P Lustenberger, BS\*, Vincent Y Ng, MD\*, Thomas M Best, MD, PhD†, and Thomas J Ellis, MD\*

\*Department of Orthopaedic Surgery, The Ohio State University Sports Medicine Center, The Ohio State University, Columbus, Ohio

†Department of Family Medicine, The Ohio State University Sports Medicine Center, The Ohio State University, Columbus, Ohio

### Abstract

**Objective**—Trochanteric bursitis (TB) is a self-limiting disorder in the majority of patients and typically responds to conservative measures. However, multiple courses of nonoperative treatment or surgical intervention may be necessary in refractory cases. The purpose of this systematic review was to evaluate the efficacy of the treatment of TB.

**Data Sources**—A literature search in the PubMed, MEDLINE, CINAHL, and ISI Web of Knowledge databases was performed for all English language studies up to April 2010. Terms combined in a Boolean search were greater trochanteric pain syndrome, trochanteric bursitis, trochanteric, bursitis, surgery, therapy, drug therapy, physical therapy, rehabilitation, injection, Z-plasty, Z-lengthening, aspiration, bursectomy, bursoscopy, osteotomy, and tendon repair.

**Study Selection**—All studies directly involving the treatment of TB were reviewed by 2 authors and selected for further analysis. Expert opinion and review articles were excluded, as well as case series with fewer than 5 patients. Twenty-four articles were identified. According to the system described by Wright et al, 2 studies, each with multiple arms, qualified as level I evidence, 1 as level II, 1 as level III, and the rest as level IV. More than 950 cases were included.

**Data Extraction**—The authors extracted data regarding the type of intervention, level of evidence, mean age of patients, patient gender, number of hips in the study, symptom duration before the study, mean number of injections before the study, prior hip surgeries, patient satisfaction, length of follow-up, baseline scores, and follow-up scores for the visual analog scale (VAS) and Harris Hip Scores (HHS).

**Data Synthesis**—Symptom resolution and the ability to return to activity ranged from 49% to 100% with corticosteroid injection as the primary treatment modality with and without multimodal conservative therapy. Two comparative studies (levels II and III) found low-energy shock-wave therapy (SWT) to be superior to other nonoperative modalities. Multiple surgical options for persistent TB have been reported, including bursectomy (n = 2), longitudinal release of the iliotibial band (n = 2), proximal or distal Z-plasty (n = 4), osteotomy (n = 1), and repair of gluteus medius tears (n = 4).

**Conclusions**—Efficacy among surgical techniques varied depending on the clinical outcome measure, but all were superior to corticosteroid therapy and physical therapy according to the VAS

---

Corresponding Author: Thomas J. Ellis, MD, Department of Orthopaedics, The Ohio State University, 2050 Kenny Rd, Columbus, OH 43221, thomas.ellis@osumc.edu.

The authors report no conflicts of interest.

and HHS in both comparison studies and between studies. This systematic review found that traditional nonoperative treatment helped most patients, SWT was a good alternative, and surgery was effective in refractory cases.

### Keywords

trochanteric bursitis; corticosteroid injection; conservative treatment; shock wave therapy

## INTRODUCTION

Trochanteric bursitis (TB) is a common problem seen by sports medicine practitioners, affecting as many as 5.6 patients per 1000 adults.<sup>1</sup> Sometimes described as “greater trochanteric pain syndrome,” TB is characterized by chronic lateral hip pain exacerbated by active abduction, passive adduction, and direct palpation.<sup>1,2</sup> The iliotibial band (ITB) and fascia lata act as a lateral tension band to resist tensile strains on the concave aspect of the femur<sup>3</sup> and is often implicated as the source of TB. Gluteus medius tears, also referred to as the “rotator cuff tears of the hip,” are found in up to 22% of elderly patients and may also be an underlying cause of lateral hip pain.<sup>4</sup> Although the incidence of TB is highest in middle-aged to elderly adults,<sup>5</sup> the etiology is multifactorial and TB can affect patients of all ages.

First described in the 1930s,<sup>6</sup> TB typically responds to conservative measures, such as activity modification, physical therapy (PT), weight loss, corticosteroid injection, and nonsteroidal anti-inflammatory medications (NSAIDs). A cure rate with such conservative interventions, administered independently or in combination, can be expected to exceed 90%.<sup>7</sup> Nevertheless, recurrence is common, and patients frequently undergo multiple courses of nonoperative treatment, experiencing only temporary and incomplete pain relief. For severe refractory cases, multiple small case series in the recent literature have described surgical options for TB. Surprisingly, there are relatively few high-level studies examining the efficacy of operative and nonoperative treatment of this often minimized yet troublesome condition. The purpose of this study was to perform a systematic review of the literature on patient satisfaction and functional outcome after different treatment modalities for TB and refractory TB.

## METHODS

A literature search of the PubMed, MEDLINE, CINAHL, and ISI Web of Knowledge databases was performed for all English language studies up to April 2010. All studies directly involving the treatment of TB were reviewed by 2 authors (D.L. and T.J.E.) and selected for further analysis. Expert opinion and review articles were excluded, as well as case series with fewer than 5 patients. The data from each study were extracted by 2 authors (D.L. and V.Y.N.).

After a thorough search of multiple medical databases (Figure 1), 24 articles met the inclusion criteria and were included in this systematic review. According to the system described by Wright et al,<sup>8</sup> 2 studies, each with multiple arms, qualified as level I evidence, 1 as level II, 1 as level III, and the rest as level IV. The average length of follow-up ranged from 4 months to 4 years. The mean age for patients in all studies was 53 years (range, 12–88 years). There were 970 hips treated in 950 patients (180 men and 706 women, excluding 1 study that did not report gender distribution<sup>9</sup>).

Using Excel (Microsoft, Redmond, Washington), a worksheet was compiled with all relevant data. The pertinent details of these studies were juxtaposed in tabular form to facilitate further review and analysis.

## RESULTS

### Nonoperative Management

Nine studies examined the effect of injection as the primary treatment modality (Table 1). The mean duration of symptoms before treatment in this group ranged from 7.1 weeks to 4.4 years. Most patients received only a single injection, but up to 33% required a second administration<sup>16</sup> and some as many as 5 injections.<sup>10</sup> All studies used a mixture of corticosteroid and local anesthetic except<sup>1,13</sup> which used methylprednisolone or triamcinolone only. Three studies of injection alone measured outcomes using the visual analog pain scale (VAS)<sup>9,12,17</sup> with a mean improvement of 2.8. Cohen et al<sup>9</sup> compared the fluoroscopically guided injection with the traditional bedside injection and found no difference. In patients with concomitant sciatica and lower back pain, Sayegh et al<sup>6</sup> demonstrated an improvement in the Oswestry Disability Index for as many as 4 years. Subjective improvement and achieving a return to the patient's baseline activity level ranged from 49% to 100%. Injections were relatively free of complications except for 1 study in which a low incidence of skin irritation, swelling, and a temporary increase in local pain were reported.<sup>17</sup>

Two studies used a multimodal conservative approach (Table 2). Furia et al<sup>11</sup> found that after a course of rest, PT, ultrasound, steroid injections, ice, and heat, 66% and 83% of patients were able to return to sports and labor-intensive occupations, respectively, after approximately 3 months. In patients with TB after total hip arthroplasty, Iorio et al<sup>15</sup> reported that all patients eventually experienced sufficient resolution after a combination of different treatment modalities. As part of a larger study, Rompe et al<sup>17</sup> assigned 76 patients to 6 weeks of a home training program consisting of piriformis and ITB stretching, gluteal strengthening, straight leg raises, and assisted squats. Only 34% were able to return to normal activity, 40.8% had significant improvement, defined as "completely recovered" or "much improved" on the Likert scale, and pain improved on average 1 point on the VAS.<sup>17</sup>

Low-energy shock-wave therapy (SWT) was examined in 2 studies<sup>11,17</sup> (Table 2). Compared with the primary outcome of other conservative measures, SWT had a superior VAS and Harris Hip Score (HHS) improvement. The mean overall VAS improvement was 3.9 (7.0 vs 3.1) for the primary outcome. Furia et al<sup>11</sup> reported a 30.3 mean increase in HHS after the treatment. Shock-wave therapy allowed 64% to 76% of patients to return to normal physical activity in the studies by Furia et al<sup>11</sup> and Rompe et al,<sup>17</sup> respectively. Minimal complications were reported, such as temporary erythema and skin irritation. However, in the study by Rompe et al,<sup>17</sup> the difference in pain and recovery at 1 month and 15 months of follow-up was not found to be statistically significant when comparing SWT with the home training group. In addition, the study by Furia et al<sup>11</sup> showed that SWT was superior to the traditional therapy used in the control group. However, no standardization of such traditional therapy occurred in the control group. In the study, traditional nonoperative therapies were defined as relative rest, anti-inflammatory medications, ice, gluteal and tensa fascia lata muscle stretching and strengthening, PT modalities, iontophoresis, a corticosteroid injection, and a local anesthetic injection.<sup>11</sup> However, no explicit delineated program for the control group is described. These study limitations weaken but do not negate the argument that SWT is superior to home or traditional therapy.

### Operative Management

All but 6 studies on the surgical treatment of TB involved either direct lengthening or release of the ITB and fascia lata. Govaert et al<sup>14</sup> described a trochanteric reduction osteotomy after which 92% of patients showed "great" or "very great" improvement of their symptoms. Of note, nearly half had a previous unsuccessful longitudinal release of the ITB

and bursectomy. Wiese et al<sup>18</sup> performed an endoscopic bursectomy without addressing the ITB and reported a mean VAS improvement of 3.4 (7.2 vs 3.8). There were 4 case series of gluteus medius repair as the main goal of surgery. The only one to offer comparative outcome scores had a failure rate of 31% (5 of 16) due to rerupture or infection but reported a VAS improvement of 5 (7 vs 2) in the remaining cases.<sup>29</sup> Three studies reported high success rates (88%–100%) of pain relief and only a single complication, persistent abductor weakness due to denervation of the gluteus medius.<sup>26–28</sup>

There were 3 predominant methods of relaxing the ITB: proximal Z-plasty, proximal longitudinal release, and distal Z-plasty. Both types of proximal procedures included bursectomy and local debridement. All studies reported a significant improvement of symptoms or satisfaction rates of 72% to 100%. Because multiple various outcome measures were used, it was difficult to compare the results of different surgical methods. Including those studies that used the VAS, mean improvement was greatest for distal Z-plasty (7.0) compared with proximal Z-plasty (5.6) and longitudinal release (4.1). When the HHS improvement was considered, proximal Z-plasty (36) was slightly superior to longitudinal release (32) and distal Z-plasty (30). Only minor surgical complications were reported; several patients had hematoma or seroma, and 1 required removal of the hardware after osteotomy.

## DISCUSSION

Lateral hip pain is a common complaint addressed by orthopedists, sports medicine specialists, and primary care physicians. Although it can arise from numerous different underlying acute and chronic pathologies, it is frequently diagnosed as TB and almost universally treated initially with conservative measures. Nevertheless, it can be a frustrating syndrome to patients and clinicians alike, and many are unaware of the availability and efficacy of more advanced therapeutic options. The challenging nature of accurately diagnosing TB as a cause of lateral hip pain is undeniable. The studies included in this systematic review, due to clinician-to-clinician variability and a lack of universal explicit criteria, did not have the same diagnostic accuracy for pinpointing TB as a source of lateral hip pain. This lack of universality in diagnosis is a limitation when comparing results between the studies.

This systematic review summarizes and clarifies several important points regarding the treatment of TB. The majority of patients with TB are treated with nonoperative modalities. For most patients, a single corticosteroid injection provides a tangible improvement in symptoms and decrease in pain from a moderate to a low level. Older studies from the 1980s tend to report better subjective responses to injection than more recent articles but typically lack validated clinical outcome scores. In some cases of TB, multiple injections and other modalities, such as PT, ultrasound, and NSAIDs, are necessary. Although 2 of the studies in this review found benefit from SWT, other conservative therapies, such as home exercise programs, have scant evidence for efficacy in the literature. Future research should be directed toward addressing this paucity of validated data supporting conservative therapies. Low-energy SWT has been shown to be superior to corticosteroid injection and home therapy and may be the next step for patients who fail conservative management. However, it has not been examined specifically in this refractory group. On the other hand, surgical treatment has demonstrated success in these patients. There are several options to consider; the least invasive is endoscopic bursectomy, and the most invasive is open osteotomy. Repairing tears to gluteus medius and gluteus minimus has also been shown to be quite beneficial in managing recalcitrant lateral hip pain, and the possibility of such tears as an underlying etiology warrants careful consideration. However, in the reported series, concomitant bursectomy or ITB windowing procedures were performed. This makes it

difficult to determine the contribution of the gluteal muscle repair to the overall improvement from the surgery. The most common procedures focus on relieving the tension of the ITB with either longitudinal release or Z-plasty.

To the authors' knowledge, this is the first systematic review of the treatment of TB despite a plethora of case series in the literature. There is a paucity of high level of evidence studies focusing on surgical modalities, and the variation in outcome measure tools preclude easy comparison across multiple studies. According to the VAS, the efficacy of treatment of TB is graded as follows, in ascending order: home therapy only, multimodal conservative therapy including injection, injection alone, bursectomy alone, low-energy SWT, longitudinal ITB release, proximal Z-plasty, and distal Z-plasty. Likewise, using the HHS, the efficacy is graded as follows: multimodal conservative therapy, including injection, distal Z-plasty, low-energy SWT, longitudinal release, and proximal Z-plasty. With only 1 of the 4 studies included in this review reporting outcome scores, repair of the abductor tendons was difficult to compare with other techniques but subjectively was successful in most patients and may be useful to combine with the treatment of ITB. This systematic review finds that although TB is one of the most common pain syndromes in adults, more clinical data are required to improve the methods of treatment.

## Acknowledgments

No financial support was received for this study.

## References

1. Brinks A, van Rijn R, Bohnen A, et al. Effect of corticosteroid injection for trochanter pain syndrome: design of a randomised clinical trial in general practice. *BMC Musculoskelet Disord.* 2007; 8:95. [PubMed: 17880718]
2. Karpinski M, Piggott H. Greater trochanteric pain syndrome. A report of 15 cases. *J Bone Joint Surg Br.* 1985; 67:762–763. [PubMed: 4055877]
3. Radin E. Biomechanics of the human hip. *Clin Orthop Relat Res.* 1980; 152:28–34. [PubMed: 7438616]
4. Bunker T, Esler C, Leach W. Rotator-cuff tear of the hip. *J Bone Joint Surg Br.* 1997; 79:618–620. [PubMed: 9250749]
5. Lievense A, Bierma-Zeinstra S, Schouten B, et al. Prognosis of trochanteric pain in primary care. *Br J Gen Pract.* 2005; 55:199–204. [PubMed: 15808035]
6. Sayegh F, Potoupnis M, Kapetanos G. Greater trochanter bursitis pain syndrome in females with chronic low back pain and sciatica. *Acta Orthop Belg.* 2004; 70:423–428. [PubMed: 15587030]
7. Brooker AJ. The surgical approach to refractory trochanteric bursitis. *Johns Hopkins Med J.* 1979; 145:98–100. [PubMed: 470296]
8. Wright J, Swiontkowski M, Heckman J. Introducing levels of evidence to the journal. *J Bone Joint Surg Am.* 2003; 85:1–3. [PubMed: 12533564]
9. Cohen S, Strassels S, Foster L, et al. Comparison of fluoroscopically guided and blind corticosteroid injections for greater trochanteric pain syndrome: multicentre randomised controlled trial. *BMJ.* 2009; 338:986–988.
10. Farmer K, Jones L, Brownson K, et al. Trochanteric bursitis after total hip arthroplasty. *J Arthroplasty.* 2010; 25:208–212. [PubMed: 19261433]
11. Furia J, Rompe J, Maffulli N. Low-energy extracorporeal shock wave therapy as a treatment for greater trochanteric pain syndrome. *Am J Sports Med.* 2009; 37:1806–1813. [PubMed: 19439756]
12. Shbeeb M, O'Duffy J, Michet CJ, et al. Evaluation of glucocorticosteroid injection for the treatment of trochanteric bursitis. *J Rheumatol.* 1996; 23:2104–2106.
13. Rasmussen K, Fano N. Trochanteric bursitis. Treatment by corticosteroid injection. *Scan J Rheumatol.* 1985; 14:417–420.

14. Govaert L, van der Vis H, Marti R, et al. Trochanteric reduction osteotomy as a treatment for refractory trochanteric bursitis. *J Bone Joint Surg Br.* 2003; 85:199–203. [PubMed: 12678352]
15. Iorio R, Healy W, Warren P, et al. Lateral trochanteric pain following primary total hip arthroplasty. *J Arthroplasty.* 2006; 21:233–236. [PubMed: 16520212]
16. Raman D, Haslock I. Trochanteric bursitis a frequent cause of ‘hip’ pain in rheumatoid arthritis. *Ann Rheum Dis.* 1982; 42:591–592. [PubMed: 6625707]
17. Rompe J, Segal N, Cacchio A, et al. Home training, local corticosteroid injection, or radial shock wave therapy for greater trochanteric pain syndrome. *Am J Sports Med.* 2009; 37:1981–1990. [PubMed: 19439758]
18. Wiese M, Rubenthaler F, Willburger R, et al. Early results of endoscopic trochanter bursectomy. *Int Orthop.* 2004; 28:218–221. [PubMed: 15197493]
19. Craig R, Gwynne Jones D, Oakley A, et al. Iliotibial band Z-lengthening for refractory trochanteric bursitis (greater trochanteric pain syndrome). *ANZ J Surg.* 2007; 77:996–998. [PubMed: 17931265]
20. Chirputkar K, Weir P, Gray A. Z-lengthening of the iliotibial band to treat recalcitrant cases of trochanteric bursitis. *Hip Int.* 2007; 17:31–35. [PubMed: 19197840]
21. Slawski D, Howard R. Surgical management of refractory trochanteric bursitis. *Am J Sports Med.* 1997; 25:86–89. [PubMed: 9006699]
22. Baker CJ, Massie R, Hurt W, et al. Arthroscopic bursectomy for recalcitrant trochanteric bursitis. *Arthroscopy.* 2007; 23:827–832. [PubMed: 17681203]
23. Schapira D, Nahir M, Scharf Y. Trochanteric bursitis: a common clinical problem. *Arch Phys Med Rehabil.* 1986; 67:815–817. [PubMed: 3778178]
24. Pretell J, Ortega J, Garcia-Rayó R, et al. Distal fascia lata lengthening: an alternative surgical technique for recalcitrant trochanteric bursitis. *Int Orthop.* 2009; 33:1223–1227. [PubMed: 19214507]
25. Sayed-Noor A, Pederson E, Wretenberg P, et al. Distal lengthening of ilio-tibial band by Z-plasty for treating refractory greater trochanteric pain after total hip arthroplasty (Pederson-Noor operation). *Arch Orthop Trauma Surg.* 2009; 129:597–602. [PubMed: 18622622]
26. Kagan A. Rotator cuff tears of the hip. *Clin Orthop Relat Res.* 1999; 368:135–140. [PubMed: 10613161]
27. Lequesne M, Djian P, Vuillemin V, et al. Prospective study of refractory greater trochanter pain syndrome. MRI findings of gluteal tendon tears seen at surgery. Clinical and MRI results of tendon repair. *Joint Bone Spine.* 2008; 75:458–464. [PubMed: 18450496]
28. Voos J, Shindle M, Pruett A, et al. Endoscopic repair of gluteus medius tendon tears of the hip. *Am J Sports Med.* 2009; 37:743–747. [PubMed: 19204363]
29. Davies H, Zhaeentan S, Tavakkolizadeh A, et al. Surgical repair of chronic tears of the hip abductor mechanism. *Hip Int.* 2009; 19:372–376. [PubMed: 20041385]




Figure 1.



Table 1

Author/Year	Treatment	Level of Evidence	Mean Age (Range), y	SWT vs Traditional Modalities (Corticosteroid Injection and/or Conservative Therapy)		Length of Follow-up	Baseline Score	Follow-up Score	Patient Satisfaction	Complications
				Males/Females/No. Hips Treated	Mean No. Injections Before Study					
Rompe et al <sup>17</sup> /2009	Arm 1: Home training program Arm 2: Repetitive low-energy radial SWT Arm 3: Single CS inj	I, Randomized controlled clinical trial	46 47 50	23/53/76 23/55/78 21/54/75	NR	4 mo	VAS 5.2; Likert 2.8	VAS 5.2; Likert 2.8	34% RTA	Increased pain (1 d: 9%; >1 d: 20%); radiating pain (6%)
							VAS 6.3; Likert 4	VAS 3.2; Likert 2.6	64% RTA	Increased pain (1 d: 10%; >1 d: 2%); radiating pain (4%); skin irritation (33%); swelling (3%)
							VAS 5.8; Likert 4	VAS 4.5; Likert 2.6	49% RTA	Increased pain (1 d: 10%; >1 d: 25%); radiating pain (9%); skin irritation (3%); swelling (9%)
Furia et al <sup>11</sup> /2009	Arm 1: Low-energy extracorporeal SWT Arm 2: Rest, PT, U/S, CS inj, ice/heat	III, Case-control study	51 (18–71) 50.2 (18–74)	11/22/33 11/22/33	At least 1	12 mo	VAS 8.5; HHS 49.6; R/M 4	VAS 2.7; HHS 79.9; R/M 2	13/17 return to sports; 10/15 return to sports; 5/6 return to labor	Pain during treatment (2); erythema (2); None
							VAS 8.5; HHS 50.4; R/M 5	VAS 6.3; HHS 57.6; R/M 2.9	None	None
Raman et al <sup>16</sup> /1982	Single CS inj (33% two)	IV, Case series	NR (NR)	1/14/15	None	16 wk	NR	NR	100% pain free	NR
Shbeeb et al <sup>12</sup> /1996	Single CS inj	IV, Case series	66.2 (NR)	13/62/75	None	26 wk	VAS 64.7	VAS 32.3	54/68 improved	NR
Rasmussen and Fano <sup>13</sup> /1985	1 or 2 CS inj	IV, Case series	57.9 (16–82)	7/29/36	None	23.2 mo	NR	NR	66% excellent; 33% improved; 25% relapse at mean 10 mo	None
Cohen et al <sup>9</sup> /2009	Arm 1: Fluoroscopically guided single CS inj Arm 2: Single CS inj	I, Randomized controlled clinical trial	NR (“most mid-50’s”)	“Most women”/32	NR	3 mo	VAS 5.1	VAS 2.7	50% had positive global perceived effect	NR
							VAS 4.6	VAS 2.2	53% had positive global perceived effect	NR



Author/Year	Treatment	Level of Evidence	Mean Age (Range), y	Males/Females/No. Hips Treated	Symptom Duration Before Study	Mean No. Injections Before Study	Length of Follow-up	Baseline Score	Follow-up Score	Patient Satisfaction	Complications
Schapira et al <sup>23</sup> /1986	CS inj (48 single; 13 two; 4 three)	IV, Case series	NR (34–79)	24/48/65	NR	NR	2 y	NR	NR	100% rapid and prolonged improvement	None
Sayegh et al <sup>16</sup> /2004	Single CS inj after failing “conservative therapy”	II, Prospective comparative study	49.6 (24–84)	0/150/163	7.1 wk	NR	Up to 4 y	ODI 68.9	ODI 3.8 (1 mo), 5.8 (1 y), 41.6 (4 y)	NR	NR
Karpinski and Piggott <sup>2</sup> /1985	Single CS inj (1 two), ultrasound, massage	IV, Case series	43 (12–59)	4/11/15	22 mo	None	36 mo	NR	NR	12/15 improved; 3 little/no relief	NR
Farmer et al <sup>10</sup> /2010	Single CS inj (7 two, 3 four, 1 five), NSAIDs and PT as needed	IV, Case series	60 (32–88)	9/13/25	8.5 mo	None	NR	NR	NR	20/25 resolved symptoms	2/2 of the 5 with persistent symptoms resolved after bursectomy
Iorio et al <sup>15</sup> /2006	CS inj alone (9), PT/US/HP (6), CS inj/PT/US/HP (4), PT/NSAID/HP (2), Obs (2), NSAID alone (1)	IV, Case series	73.5 (58–87)	CS inj or Other Conservative Interventions 7/17/24	NR	None	3 y	NR	NR	All resolved sufficiently; no further treatment needed	NR

CS inj, corticosteroid injection; HP, home program; HQI, health quality index; NR, not reported; Obs, observation; ODI, Oswestry Disability Index; OH, Oxford hip score; R/M, roles and maudslley score; RTA, return to activity; US, ultrasound; VAS, visual analog scale.

Table 2

Author/Year/Intervention	Mean Length of Follow-up	Baseline Score	Follow-up Score	Patient Satisfaction	Complications
Sayed-Noor et al <sup>25</sup> /2009/distal ITB Z-plasty	27 mo	HQI 34; EQ-5 D questionnaire 0.26	HQI 60; EQ-5 D 0.67	7/12 improved; 4/12 gradual improvement; 1/12 no improvement	None
Trochanteric osteotomy					
Govaert et al <sup>14</sup> /2003/trochanteric osteotomy	23.5 y	MDP 15.8	MDP 27.5	6/12 very great improvement; 5/12 great; 1/12 fair	Hematoma/calcification (1), gluteal pain (1), fell/displaced trochanter (1), ROH (1)
Gluteus medius repair with other selected interventions					
Kagan <sup>26</sup> /1999/gluteus medius repair (fasciotomy in 4)	42 mo	NR	NR	All satisfied; full pain relief	Weakness, denervation of gluteus medius (1)
Lequesne et al <sup>27</sup> /2008/gluteus medius repair, bursectomy (gluteus minimus repair in 5)	29.4 mo	NR	NR	7/8 complete pain relief; 1/8 partial pain relief	None
Voos et al <sup>28</sup> /2009/endoscopic gluteus medius repair, bursectomy (8 labral debridement, 1 labral repair, 1 greater trochanter exostectomy, 1 pincer lesion debridement, 1 ITB release, 2 psoas tendon release)	25 mo	NR	HHS 94; Hip outcome score 93	All complete resolution of pain; 1 with new groin pain	None
Davies et al <sup>29</sup> /2009/gluteus medius, minimus repair, bursectomy	12 mo	Excluding failures: VAS 7; MDP 10.5; OH 21.4; SF-36 (Phys 28.4, Ment 54.9)	Excluding failures: VAS 2; MDP 15; OH 38; SF-36 (Phys 40.2, Ment 59.4)	11/16 significant improvement in hip symptoms; 5/16 surgical failures	Reruptures (4), deep infection (1)

All listed studies are level IV Evidence Case Series.

CS Inj, corticosteroid injection; HP, home program; HQI, health quality index; JOA, Japanese Orthopaedic Association; Ment, mental portion; MDP, Merle D'Aubigne Postel score; NR, not reported; Obs, observation; ODI, Oswestry Disability Index; OH, Oxford hip score; Phys, physical portion; PT, physical therapy; R/M, Roles and Maudsley score; ROH, removal of hardware; SF-36, short form 36; US, ultrasound.